---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-140688"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T19:50:32.599773+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aileron Therapeutics appoints Timothy Cunningham as interim CFO after Charles Garner departure

## Summary
- Charles Garner departed as CFO on May 15, 2024; Timothy Cunningham appointed interim CFO effective May 16, 2024.
- Cunningham is a consultant from Danforth Advisors, providing CFO services at an hourly rate under consulting agreement.
- Cunningham, age 62, CPA, has served as CFO for Bionomics Limited and other biotech firms; no family relationships with executives.

## SEC filing metadata
- accession: 0001193125-24-140688
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/0001193125-24-140688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/d841479d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-140688
- JSON: https://secwatch.observer/filing/0001193125-24-140688.json
- Plain text: https://secwatch.observer/filing/0001193125-24-140688.txt

## Key facts
- Executive change
  Timothy M. Cunningham was appointed as Interim Chief Financial Officer at Rein Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/0001193125-24-140688-index.htm
- Executive change
  Charles Garner departed as Chief Financial Officer at Rein Therapeutics, Inc..
  - Action: departed
  - Role: Chief Financial Officer
  source text: Mr. Garner's departure from the Company on May 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/0001193125-24-140688-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.